Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Altamira Therapeutics Ltd
CYTOCurrent price
0.75 USD
+0.008 USD (+1.08%)
Last closed
0.75 USD
Company
altamiratherapeutics.com
ISIN
BMG0360L1000
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
2 713 636 USD
Yield for 12 month
-85.18 %
1Y
3Y
5Y
10Y
15Y
CYTO
Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase II/III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It also offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is based in Hamilton, Bermuda. Address: Clarendon House, Hamilton, Bermuda, HM 11
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
8.23 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
+361 889 USD
Current Quarter
+62 445 USD
Last Quarter
+62 445 USD
Current Year
–
Last Year
-1 347 824 USD
Current Quarter
-63 181 USD
Last Quarter
-63 181 USD
Key Figures CYTO
1 year
3 years
5 years
10 years
EBITDA
-5 796 795 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-52.83 %
PEG Ratio
–
Return On Equity TTM
-964.17 %
Wall Street Target Price
8.23 USD
Revenue TTM
120 287 USD
Book Value
4.37 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-63.7 %
Dividend Yield
–
Gross Profit TTM
-2 176 672 USD
Earnings per share
-17.36 USD
Diluted Eps TTM
-17.36 USD
Most Recent Quarter
II 2023
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics CYTO
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History CYTO
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:20
Payout Ratio
–
Last Split Date
13.12.2023
Dividend Date
01.05.2019
Stock Valuation CYTO
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
64.9314
Price Sales TTM
0.6382
Enterprise Value EBITDA
-0.4688
Price Book MRQ
0.3583
Financials CYTO
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators CYTO
For 52 weeks
0.73 USD
17.2 USD
50 Day MA
1.05 USD
Shares Short Prior Month
159 812
200 Day MA
2.03 USD
Short Ratio
0.2
Shares Short
180 201
Short Percent
5.61 %
BeatStart